0001140361-15-023164.txt : 20150603 0001140361-15-023164.hdr.sgml : 20150603 20150603202731 ACCESSION NUMBER: 0001140361-15-023164 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150529 FILED AS OF DATE: 20150603 DATE AS OF CHANGE: 20150603 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SPIEGELMAN DANIEL K CENTRAL INDEX KEY: 0001238403 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 15911662 MAIL ADDRESS: STREET 1: 3172 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94034 4 1 doc1.xml FORM 4 X0306 4 2015-05-29 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001238403 SPIEGELMAN DANIEL K C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST. SAN RAFAEL CA 94901 0 1 0 0 EVP, Chief Financial Officer Common Stock 2015-05-29 2015-05-29 4 F 0 4305 125.57 D 37202 D Common Stock 2015-05-29 2015-05-29 4 S 0 1578 126.1502 D 35624 D Common Stock 2015-06-01 2015-06-01 4 S 0 3945 124.16 D 31679 D This transaction, which should have been reported on June 2, 2015, is being reported late due to an administrative oversight. Trade made pursuant to a 10b5-1 plan executed on March 11, 2015. The price in column 4 is a weighted average price. The price actually received ranged from $125.60 to $127.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is a weighted average price. The price actually received ranged from $123.06.60 to $124.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. /s/ Laura Randall Woodhead, Attorney-in-Fact 2015-06-02